CD38 and neoplasm: It has been shown that shedding or transfer of daratumumab-CD38 complexes from tumor cells to extracellular fluids (“capping” followed by shedding) or to immune effector cells (“trogocytosis”) may result in reduced levels of CD38 on the tumor cell surface [9,10].